4.6 Review

Practical guidelines for managing adults with 22q11.2 deletion syndrome

期刊

GENETICS IN MEDICINE
卷 17, 期 8, 页码 599-609

出版社

ELSEVIER SCIENCE INC
DOI: 10.1038/gim.2014.175

关键词

22q11.2 deletion; clinical practice guidelines; DiGeorge syndrome; treatment; velocardiofacial syndrome

资金

  1. Canadian Institutes of Health Research (CIHR) [MOP 97800, MOP 111238]
  2. Canada Research Chairs program
  3. Dempster Family Foundation Canada
  4. CIHR
  5. Brain Canada Mental Health Training Award
  6. CIHR Vanier Canada Graduate Scholarship
  7. McLaughlin Centre MD/PhD studentship
  8. Dalglish Family Hearts and Minds Clinic Fellowship
  9. NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH101723] Funding Source: NIH RePORTER

向作者/读者索取更多资源

22q11.2 Deletion syndrome (22q11.2DS) is the most common microdeletion syndrome in humans, estimated to affect up to 1 in 2,000 live births. Major features of this multisystem condition include congenital anomalies, developmental delay, and an array of early- and later-onset medical and psychiatric disorders. Advances in pediatric care ensure a growing population of adults with 22q11.2DS. Informed by an international panel of multidisciplinary experts and a comprehensive review of the existing literature concerning adults, we present the first set of guidelines focused on managing the neuropsychiatric, endocrine, cardiovascular, reproductive, psychosocial, genetic counseling, and other issues that are the focus of attention in adults with 22q11.2DS. We propose practical strategies for the recognition, evaluation, surveillance, and management of the associated morbidities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据